Cencora, Inc. $COR Stock Holdings Decreased by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. decreased its stake in shares of Cencora, Inc. (NYSE:COR) by 12.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,522 shares of the company’s stock after selling 1,764 shares during the period. Stanley Laman Group Ltd.’s holdings in Cencora were worth $3,914,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in Cencora by 5.3% during the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after acquiring an additional 284,229 shares during the last quarter. Norges Bank bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $695,215,000. Viking Global Investors LP raised its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. Finally, Amundi lifted its stake in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after purchasing an additional 249,742 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 20,317 shares of company stock valued at $7,009,260. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $338.87 on Monday. The firm’s 50 day moving average is $349.59 and its two-hundred day moving average is $316.84. Cencora, Inc. has a 52 week low of $225.75 and a 52 week high of $377.54. The firm has a market capitalization of $65.74 billion, a P/E ratio of 42.63, a PEG ratio of 1.61 and a beta of 0.66. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Barclays started coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 target price for the company. UBS Group lifted their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wells Fargo & Company boosted their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $373.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.